BIOSTAGE, INC. (NASDAQ:BSTG) Files An 8-K Results of Operations and Financial Condition

BIOSTAGE, INC. (NASDAQ:BSTG) Files An 8-K Results of Operations and Financial Condition
Item 2.02.

On August 13, 2019, Biostage, Inc. issued a press release announcing financial results for the three and six months ended June 30, 2019. The press release, or the Press Release, is furnished as Exhibit 99.1 and incorporated herein by reference.

The information in this Items 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

(d) Exhibits.

Exhibit Number Title
99.1 Press Release issued by Biostage, Inc. on August 13, 2019

Biostage, Inc. Exhibit
EX-99.1 2 tv527460_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1   Biostage Reports Second Quarter 2019 Financial Results   –        Preparing to file first IND in September 2019     Holliston,…
To view the full exhibit click here

Story continues below


Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.

An ad to help with our costs